The IDI

The IDI

By Valuate Health ConsultancyScienceMedicineHealth & FitnessLife Sciences
Download on the App Store

The IDI episodes

  • How Pharma Can Turn Data into Insights

    Every pharma company wants to analyze and leverage their data for other purposes. 

    But what if you’re not a data scientist? Or maybe your data is messy; did you even know data can be messy?

    Derek Tancredi and Terrill Paterson deal with these challenges all the time as they work with pharma and market access teams.

    Derek is a consultant at Valuate Health with an MBA in Health Care Administration. Terrill Paterson is a Senior Analyst with Valuate. He holds a Masters in Statistics and a PhD in Environmental Science. 

    Follow Derek on LinkedIn.

    Follow Terrill on LinkedIn.

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

    33 min
  • ChatGPT Comes to Market Access

    ChatGPT, the artificial intelligence tool that generates text and allows you to have human-like conversations, was released in November of last year. 

    Today, you can ask  ChatGPT to write a business plan to commercialize market access for your new prescription drug -- and it will do so in seconds.

    Bill Pittenger, SVP, Director of Digital Growth & Operations for Entrée Health, is experimenting with ChatGPT and other AI tools for market access. Bill explains how and why ChatGPT and other AI tools will transform market access for the better in today's episode.

    Follow Bill Pittenger on LinkedIn.

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

    28 min
  • What's Working in Hub Services

    Hub services sound great in theory. But in practice, hub services can be a challenge for the patient and the manufacturer. 

    DeWayne Manning is a partner with Archbow Consulting and an expert on hub services. DeWayne has more than 25 years of experience advising clients on specialty products, reimbursement, patient access programs, business process optimization, technology integration, and data management  

    Follow DeWayne Manning on LinkedIn.

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

    26 min
  • Cancer Care: Major Progress and New Challenges

    The good news: The cancer death rate in America has fallen 33% since 1991. 

    The bad news: The cost for treatment remains a huge barrier for some patients.

    One recent study put the economic and human costs of cancer in adolescents and young adults at $23.5 billion overall -- nearly $260,000 per  patient.

    To get a sense of how to improve access and affordability, The IDI host Ira Apfel spoke to John Hennessy and Matt Farber.

    Hennessy is a Principal at Valuate and a former executive director of the Kansas City Cancer Center, and former executive director the community cancer program at the University of Kansas Hospital. 

    Farber is the vice president for Enterprise Partnerships with OffScrip Health, one of the fastest-growing patient access, impact, and content influencers in the country.  

    Follow John Hennessy on LinkedIn.

    Follow Matt Farber on LinkedIn.

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

    33 min
  • What's Trending in Market Access and Pharma?

    A recent article in Pharmaceutical Executive listed 10 market access trends shaping the post-pandemic world -- and one of the contributors was Andrew Gottfried, CEO of Entree Health, an access and reimbursement communications agency. 

    In a wide-ranging episode of The IDI, Andrew discussed global access and storytelling, the Inflation Reduction Act, the post-pandemic world, and more.

    Connect with Andrew Gottfried on LinkedIn.

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

    16 min
  • The State of Market Access

    2022 was a year of uncertainty for pharma and market access. So we figured it was a good time to ask  payer executives for their thoughts on the subject -- and gain some insights from their responses. 

    Susan Weber, today's guest on The IDI, wrote and supervised the survey. She's the best person to interpret the findings and draw some lessons for market access professionals. 

    Connect with Susan Weber on LinkedIn.

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

     

    23 min
  • How the Inflation Reduction Act Will Impact Pharma

    When President Biden signed the Inflation Reduction Act into law earlier this year, he set the stage for some of the biggest changes the pharmaceutical industry has seen in years. So how should pharma prepare for the IRA? 

    Diane Petrone and Jim Kenney, principal consultants with Valuate Health, join The IDI to discuss what they're hearing from pharma clients about the IRA; which aspects of the IRA  will have the biggest impact on pharma; why removing some drug rebate calculations (as laid out in the IRA) is a big deal; and more. 

    Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

    24 min
  • Pharma and Data Analytics: What's the Right Approach?

    Pharmaceutical manufacturers today rely on data in everything from accelerating drug development and improving the efficacy of clinical trials to reducing safety concerns and identifying patient populations.

    But the sheer amount of data can be overwhelming. Too often it’s hard to figure out where to get started in the data analytics part. What do you want to know from the data? What are the right questions to ask of the data? And is this even the right data to use?

    Jack Timko, a principal with Valuate Health who leads their data analytics team, joins The IDI to help make sense of data and data analytics in pharma and market access.

    Connect with Jack Timko on LinkedIn

    Learn more about Valuate Health

    30 min
  • Health Equity and Pharma: Where to Begin?

    Health equity is a big topic in the pharmaceutical industry right now, but the topic is so large that manufacturers don't know where to start. Tony Gibson, MHA, a Principal at Valuate Health, has some advice on how pharma can address health equity in a meaningful way.

    Manufacturers have shown a “tremendous willingness to incorporate the voice of the patient,” Gibson says. But their health equity messaging tends to be the weak link. “It can come off as window dressing which minimizes this very important topic and reduces it to a catch phrase,” he says.

    Connect with Tony on LinkedIn

    Gibson recently contributed to a white paper on health equity and pharma.

    Download the health equity and pharma white paper

    25 min

About The IDI

From the publisher's feed

The IDI is a podcast by and for market access professionals. Each episode, we conduct in-depth interviews to get payer insights that help you optimize your value strategy and commercialization – and give people access to the heath care they deserve.